• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

27.23 +0.33 (+1.23%)
Streaming Delayed Price Updated: 1:35 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arvinas Inc

< Previous 1 2 3 Next >
Arvinas to Participate in Upcoming Investor Conferences
Today 7:00 EST
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 30, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
October 22, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High
February 06, 2024
Via Investor Brand Network
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
October 21, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
August 29, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 30, 2024
From Arvinas Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
July 22, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
June 24, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 21, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
June 03, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Upcoming Investor Conferences
May 02, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
March 18, 2024
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - 
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
March 04, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Chief Financial Officer Transition
February 20, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 20, 2024
From Arvinas Inc.
Via GlobeNewswire
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
February 14, 2024
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 06, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
February 01, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Jared Freedberg as General Counsel
January 16, 2024
Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) 
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From Arvinas Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap